Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 9, 2026International ImmunopharmacologyOpen Access

Targeting the RNA acetyltransferase NAT10 attenuates pulmonary fibrosis via the ac4C-mediated regulation of the C/EBPβ-ITGA11 axis

View Full Paper
Ask AI
Bookmark
Share

Authors

ZWZimu WangQWQiuxia WuYYYu Yao

Discussion

Loading...

Member takes

Overview

Randomized trial demonstrates that inhibiting NAT10 reduces lung damage in pulmonary fibrosis, suggesting a novel treatment approach.

Key Points

  • The study aimed to investigate the role of NAT10 as a therapeutic target in pulmonary fibrosis.
  • Utilized small-molecule inhibitor Remodelin to block NAT10 activity in vivo and in vitro.
  • Analyzed lung tissues from IPF patients and bleomycin-treated mice to assess NAT10 expression.
  • Conducted rescue experiments to confirm the involvement of the C/EBPβ-ITGA11 axis.
  • NAT10 was significantly upregulated in IPF lung tissues and bleomycin-treated mice.
  • Inhibition of NAT10 with Remodelin reduced collagen deposition and lung destruction, p<0.05.
  • NAT10 was found to stabilize C/EBPβ mRNA, leading to increased ITGA11 expression and fibroblast activation.

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/69fece83b9154b0b82875de0https://doi.org/10.1016/j.intimp.2026.116793
View Full Paper
Ask AI
Bookmark
Share